Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community-Acquired Infections | 15 | 2026 | 95 | 3.250 |
Why?
|
| Pneumonia | 11 | 2024 | 295 | 2.350 |
Why?
|
| Cross Infection | 8 | 2024 | 170 | 1.970 |
Why?
|
| Anti-Bacterial Agents | 19 | 2026 | 807 | 1.420 |
Why?
|
| Pneumonia, Bacterial | 6 | 2019 | 91 | 1.240 |
Why?
|
| Influenza, Human | 6 | 2022 | 210 | 1.170 |
Why?
|
| Universal Precautions | 2 | 2023 | 3 | 0.930 |
Why?
|
| Guideline Adherence | 4 | 2017 | 310 | 0.930 |
Why?
|
| Pandemics | 9 | 2024 | 691 | 0.920 |
Why?
|
| Water Purification | 1 | 2025 | 9 | 0.880 |
Why?
|
| Surgical Tape | 1 | 2024 | 4 | 0.880 |
Why?
|
| Staphylococcal Infections | 2 | 2020 | 131 | 0.830 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2021 | 66 | 0.800 |
Why?
|
| Hand Disinfection | 2 | 2014 | 18 | 0.790 |
Why?
|
| Physicians | 2 | 2020 | 486 | 0.650 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 770 | 0.630 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 31 | 0.630 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2011 | 86 | 0.610 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 439 | 0.610 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 631 | 0.600 |
Why?
|
| Staphylococcus aureus | 4 | 2022 | 183 | 0.600 |
Why?
|
| Survivors | 1 | 2020 | 187 | 0.580 |
Why?
|
| Humans | 53 | 2026 | 65635 | 0.560 |
Why?
|
| Burnout, Professional | 1 | 2020 | 145 | 0.520 |
Why?
|
| Infection Control | 5 | 2024 | 106 | 0.520 |
Why?
|
| Patient Safety | 1 | 2020 | 281 | 0.490 |
Why?
|
| Quality of Health Care | 1 | 2020 | 533 | 0.460 |
Why?
|
| Immunocompromised Host | 2 | 2013 | 104 | 0.430 |
Why?
|
| Hand Hygiene | 1 | 2014 | 10 | 0.430 |
Why?
|
| Retrospective Studies | 17 | 2026 | 6948 | 0.430 |
Why?
|
| Disease Outbreaks | 3 | 2024 | 110 | 0.430 |
Why?
|
| Caliciviridae Infections | 1 | 2013 | 4 | 0.390 |
Why?
|
| Norovirus | 1 | 2013 | 7 | 0.390 |
Why?
|
| Gastroenteritis | 1 | 2013 | 15 | 0.390 |
Why?
|
| Hospitalization | 10 | 2026 | 1403 | 0.380 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 219 | 0.370 |
Why?
|
| Length of Stay | 4 | 2023 | 828 | 0.370 |
Why?
|
| United States | 16 | 2024 | 8166 | 0.360 |
Why?
|
| Seasons | 2 | 2020 | 140 | 0.340 |
Why?
|
| Myocarditis | 1 | 2011 | 68 | 0.310 |
Why?
|
| Behavior | 1 | 2010 | 36 | 0.310 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2010 | 29 | 0.310 |
Why?
|
| Hospital Mortality | 3 | 2021 | 879 | 0.300 |
Why?
|
| Respiratory Insufficiency | 2 | 2019 | 154 | 0.300 |
Why?
|
| Motivation | 1 | 2012 | 298 | 0.300 |
Why?
|
| Anti-Infective Agents | 2 | 2021 | 154 | 0.290 |
Why?
|
| Surgical Wound Infection | 1 | 2010 | 126 | 0.280 |
Why?
|
| Methicillin Resistance | 1 | 2008 | 23 | 0.270 |
Why?
|
| Clostridium Infections | 2 | 2022 | 49 | 0.270 |
Why?
|
| Adult | 14 | 2024 | 17508 | 0.260 |
Why?
|
| Ethanol | 1 | 2010 | 333 | 0.240 |
Why?
|
| Osmosis | 1 | 2025 | 6 | 0.220 |
Why?
|
| Antimicrobial Stewardship | 2 | 2026 | 21 | 0.220 |
Why?
|
| Water Supply | 1 | 2025 | 16 | 0.220 |
Why?
|
| Epidemiologists | 1 | 2024 | 1 | 0.210 |
Why?
|
| Personal Protective Equipment | 1 | 2024 | 26 | 0.210 |
Why?
|
| Resuscitation Orders | 1 | 2024 | 45 | 0.200 |
Why?
|
| Aged | 13 | 2026 | 15087 | 0.190 |
Why?
|
| Data Collection | 1 | 2024 | 384 | 0.190 |
Why?
|
| Aged, 80 and over | 9 | 2026 | 5656 | 0.180 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 80 | 0.170 |
Why?
|
| Treatment Outcome | 8 | 2017 | 5818 | 0.170 |
Why?
|
| Anaphylaxis | 1 | 2022 | 41 | 0.170 |
Why?
|
| Health Facilities | 1 | 2021 | 46 | 0.170 |
Why?
|
| Federal Government | 1 | 2021 | 18 | 0.170 |
Why?
|
| Mandatory Programs | 1 | 2021 | 17 | 0.170 |
Why?
|
| Masks | 1 | 2021 | 20 | 0.170 |
Why?
|
| Legionnaires' Disease | 1 | 2020 | 8 | 0.170 |
Why?
|
| Blood Culture | 1 | 2020 | 8 | 0.170 |
Why?
|
| Local Government | 1 | 2021 | 12 | 0.160 |
Why?
|
| State Government | 1 | 2021 | 32 | 0.160 |
Why?
|
| Drug Resistance, Microbial | 1 | 2020 | 47 | 0.160 |
Why?
|
| Fluoroquinolones | 2 | 2022 | 33 | 0.160 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2020 | 27 | 0.160 |
Why?
|
| Coinfection | 1 | 2021 | 59 | 0.160 |
Why?
|
| Microbiological Techniques | 1 | 2020 | 6 | 0.160 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 31 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 45 | 0.160 |
Why?
|
| Health Personnel | 1 | 2024 | 390 | 0.160 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2022 | 97 | 0.150 |
Why?
|
| Viruses | 1 | 2020 | 82 | 0.150 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2010 | 59 | 0.150 |
Why?
|
| Communicable Diseases | 1 | 2020 | 86 | 0.150 |
Why?
|
| International Classification of Diseases | 1 | 2020 | 136 | 0.150 |
Why?
|
| Superinfection | 2 | 2010 | 12 | 0.150 |
Why?
|
| Academic Medical Centers | 2 | 2012 | 309 | 0.140 |
Why?
|
| Calcitonin | 1 | 2017 | 17 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 205 | 0.130 |
Why?
|
| Middle Aged | 12 | 2026 | 18434 | 0.130 |
Why?
|
| Female | 13 | 2026 | 34298 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 2788 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 741 | 0.120 |
Why?
|
| Alcoholism | 1 | 2019 | 329 | 0.120 |
Why?
|
| Male | 13 | 2026 | 31285 | 0.120 |
Why?
|
| Risk Assessment | 4 | 2022 | 2113 | 0.110 |
Why?
|
| Hygiene | 1 | 2014 | 13 | 0.110 |
Why?
|
| Sepsis | 2 | 2019 | 302 | 0.110 |
Why?
|
| Antiviral Agents | 2 | 2022 | 328 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2015 | 204 | 0.100 |
Why?
|
| Risk Factors | 3 | 2020 | 5466 | 0.100 |
Why?
|
| Age Distribution | 2 | 2010 | 262 | 0.090 |
Why?
|
| Health Policy | 2 | 2024 | 191 | 0.090 |
Why?
|
| Lecithin Cholesterol Acyltransferase Deficiency | 1 | 2011 | 2 | 0.090 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 2011 | 6 | 0.090 |
Why?
|
| Homozygote | 1 | 2011 | 122 | 0.090 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 707 | 0.080 |
Why?
|
| Peer Group | 1 | 2012 | 114 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2011 | 190 | 0.080 |
Why?
|
| Gentamicins | 1 | 2010 | 24 | 0.080 |
Why?
|
| Immune Sera | 1 | 2010 | 35 | 0.080 |
Why?
|
| Sterilization | 1 | 2010 | 15 | 0.080 |
Why?
|
| Catheters, Indwelling | 1 | 2010 | 67 | 0.080 |
Why?
|
| Catheter-Related Infections | 1 | 2010 | 42 | 0.080 |
Why?
|
| Surgical Instruments | 1 | 2010 | 44 | 0.080 |
Why?
|
| Public Health | 1 | 2012 | 188 | 0.080 |
Why?
|
| Prognosis | 2 | 2019 | 1791 | 0.080 |
Why?
|
| Operating Rooms | 1 | 2010 | 60 | 0.070 |
Why?
|
| New England | 1 | 2010 | 271 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2023 | 371 | 0.070 |
Why?
|
| Heart | 1 | 2011 | 298 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2010 | 191 | 0.070 |
Why?
|
| Trauma Centers | 1 | 2010 | 130 | 0.070 |
Why?
|
| Myocardium | 1 | 2011 | 302 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 1 | 2010 | 142 | 0.070 |
Why?
|
| Methicillin | 1 | 2008 | 5 | 0.070 |
Why?
|
| Orthomyxoviridae | 1 | 2008 | 27 | 0.070 |
Why?
|
| Bacteriological Techniques | 1 | 2008 | 29 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 214 | 0.070 |
Why?
|
| Culture Media | 1 | 2008 | 78 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 253 | 0.070 |
Why?
|
| Echocardiography | 1 | 2011 | 513 | 0.070 |
Why?
|
| Influenza Vaccines | 1 | 2008 | 99 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2010 | 744 | 0.060 |
Why?
|
| Hospitals | 2 | 2020 | 398 | 0.050 |
Why?
|
| Young Adult | 2 | 2014 | 4855 | 0.050 |
Why?
|
| Strategic Stockpile | 1 | 2024 | 1 | 0.050 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2024 | 23 | 0.050 |
Why?
|
| Time Factors | 2 | 2010 | 3777 | 0.050 |
Why?
|
| Disaster Planning | 1 | 2024 | 57 | 0.050 |
Why?
|
| Adolescent | 2 | 2020 | 6349 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2024 | 114 | 0.050 |
Why?
|
| Cephalosporins | 1 | 2022 | 21 | 0.050 |
Why?
|
| Macrolides | 1 | 2022 | 38 | 0.040 |
Why?
|
| Oseltamivir | 1 | 2022 | 35 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 2730 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 400 | 0.040 |
Why?
|
| Legionella pneumophila | 1 | 2020 | 10 | 0.040 |
Why?
|
| Comorbidity | 1 | 2024 | 1120 | 0.040 |
Why?
|
| Blood-Borne Pathogens | 1 | 2020 | 12 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 40 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2015 | 579 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2020 | 67 | 0.040 |
Why?
|
| Forecasting | 1 | 2021 | 231 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 61 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 170 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 463 | 0.040 |
Why?
|
| Pneumonia, Aspiration | 1 | 2019 | 15 | 0.040 |
Why?
|
| Communication | 1 | 2024 | 606 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 514 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 181 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2015 | 2639 | 0.030 |
Why?
|
| Inpatients | 1 | 2020 | 322 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 1172 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1116 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 405 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 888 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 1567 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 78 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1580 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 931 | 0.030 |
Why?
|
| Nursing Homes | 1 | 2020 | 692 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2015 | 126 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1288 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 1225 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 2319 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1487 | 0.020 |
Why?
|
| Corneal Opacity | 1 | 2011 | 4 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 37 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2011 | 23 | 0.020 |
Why?
|
| Proteinuria | 1 | 2011 | 41 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 35 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 202 | 0.020 |
Why?
|
| Cholesterol | 1 | 2011 | 261 | 0.020 |
Why?
|
| Endocarditis, Bacterial | 1 | 2010 | 36 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 417 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 413 | 0.020 |
Why?
|
| Shock, Septic | 1 | 2010 | 89 | 0.020 |
Why?
|
| Heparin | 1 | 2010 | 120 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 373 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 1588 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2010 | 498 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2010 | 318 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 252 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2010 | 529 | 0.010 |
Why?
|
| Vaccination | 1 | 2008 | 388 | 0.010 |
Why?
|
| Massachusetts | 1 | 2010 | 2154 | 0.010 |
Why?
|
| Infant | 1 | 2008 | 1711 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 2496 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 21450 | 0.010 |
Why?
|
| Pregnancy | 1 | 2008 | 2392 | 0.010 |
Why?
|